How safe is Wegovy long term, and what does the evidence show?

What does long-term use actually look like in the trial data?

Most weight-loss trial programmes run for around 68 to 72 weeks, which already puts Wegovy ahead of many treatments in terms of how much safety data existed at the point of licensing. The SELECT trial went further: it enrolled adults with pre-existing cardiovascular disease and no diabetes, and tracked them for a median of over four years at the 2.4mg weekly dose. It found a significant reduction in major cardiovascular events (heart attack, stroke or cardiovascular death) compared with placebo, which is why semaglutide holds a separate UK licence for cardiovascular risk reduction alongside its weight-management indication.

Side effects across the long-term studies remained consistent with the shorter-term picture: predominantly gastrointestinal, with no new serious safety signals emerging as follow-up lengthened. The MHRA continues to monitor semaglutide under its Black Triangle (▼) scheme, meaning any new information about safety is actively collected and reviewed. The NHS semaglutide medicines page summarises the current known profile for patients. That ongoing surveillance is part of how regulators ensure a medicine's benefit-risk balance holds up beyond the initial trial data.

One practical point: the question of how long it is safe to take Wegovy is genuinely individual. NICE's recommendation for semaglutide within the NHS specifies a maximum of two years within a specialist service, but that reflects NHS commissioning policy rather than a safety cut-off. Your prescriber reviews your progress, health status and any side effects at every repeat — which is how it should work for any POM.

Which side effects are common, and are they dangerous?

The most frequently reported effects are gastrointestinal: nausea is the headline one, alongside vomiting, diarrhoea, constipation, reflux and burping. These are rarely dangerous in themselves, though persistent vomiting or severe diarrhoea can occasionally lead to dehydration. Fatigue, headache and injection-site reactions also crop up. For most people the GI effects are worst in the first few weeks and after each dose increase; they typically settle as the body adjusts.

A fuller breakdown of how these effects typically unfold is covered on the Wegovy side effects page, including less common reactions. Less frequently, some people notice a persistent cough, there is a separate look at Wegovy and cough if that applies to you. The Wegovy SmPC on the eMC carries the complete list, which is worth reading alongside the patient information leaflet supplied with your pens.

On the question of whether Wegovy is safe for long-term use, the broader semaglutide safety data (including cardiovascular outcomes) is encouraging. The evidence does not suggest that extended use in appropriate patients creates new categories of risk not already present at the point of starting. That said, gallbladder problems are a recognised risk with all GLP-1 medicines, more so with significant weight loss generally, and pancreatitis (while uncommon) is listed as a known potential side effect.

When should you get medical help rather than waiting it out?

Most nausea passes. Some symptoms should not wait. Seek urgent medical attention if you develop severe, persistent stomach pain that radiates towards the back, with or without vomiting: this could indicate pancreatitis. In January 2026 the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines, the MHRA Drug Safety Update index carries the full communication for clinicians.

Other reasons to get help promptly: signs of a serious allergic reaction (facial swelling, breathing difficulty, widespread rash), severe gallbladder pain (upper-right abdominal pain, fever, jaundice), or symptoms of significant dehydration from uncontrolled vomiting or diarrhoea. If you are taking Wegovy through a private service, that includes aftercare access, use it. At nume, prescribers are available seven days a week for exactly these moments, not just at the point of order.

It is also worth knowing that if you are on oral contraceptives, semaglutide may reduce how well the pill is absorbed in the early weeks of treatment. NHS England's guidance on weight-management injections covers contraception, HRT and surgery considerations in practical detail. Bring any concerns to your prescriber before your next dose rather than stopping abruptly without advice.

How does ongoing monitoring affect long-term safety in practice?

The honest answer is that monitoring makes a substantial difference. Starting Wegovy in January, pausing over a holiday, restarting in spring, the clinical picture shifts, and what was appropriate at the beginning may need revisiting months later. If you are thinking ahead, our guide to how long it is safe to be on Wegovy explores what the evidence and clinical guidance say about duration of treatment. Long-term safety is not just about what the medicine does; it is about whether the right person is still taking the right dose with someone paying attention.

That is why, at nume, every repeat order goes through clinical review before dispatch, rather than rolling over automatically. It is also why the consultation covers your full history, not just a BMI figure. If you have specific questions about whether Wegovy suits your situation (including how long you might stay on it and what monitoring to expect) the free consultation with our prescribers is the place to raise them. For a wider comparison of semaglutide's safety profile over time, this overview of semaglutide's long-term safety record goes into further detail.